Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs
Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that labeling for

Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of interim results from its Phase II CONTROL trial of neratinib in the September 2020 Issue (Volume

Momenta Pharmaceuticals: Nächste Mega-Übernahme im US-Biotechsektor!
Momenta Pharmaceuticals: Nächste Mega-Übernahme im US-Biotechsektor!

Zuletzt verging kaum ein Tag, an dem nicht irgendeine Mega-Übernahme im US-Biotechsektor vermeldet wurde. So auch heute. Denn heute verkündete Johnson & Johnson die Übernahme von Momenta

Agilent Reports Third-Quarter Fiscal Year 2020 Financial Results
Agilent Reports Third-Quarter Fiscal Year 2020 Financial Results


Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.26 billion for the third quarter ended July 31, 2020, a decline of 1% compared to the third quarter of 2019 and down 3.1% on a core(

Premier Inc. Working with AstraZeneca to Reduce Hospitalizations of Patients with Hyperkalemia
Premier Inc. Working with AstraZeneca to Reduce Hospitalizations of Patients with Hyperkalemia


Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today it has reached a significant milestone in its partnership with AstraZeneca, a global, science-led

Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics
Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics


Agilent Technologies Inc. (NYSE: A) today announced it will expand its state-of-the-art production facility in Frederick, Colorado, that develops and manufactures “oligos,” which are short DNA and

Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology


Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that the Journal of Clinical Oncology has published results from its Phase 1 study of QINLOCK, the Company’s switch-control tyrosine

Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations
Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations


Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that data from the Phase 2 TRITON2 study of Rubraca® (rucaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Novocure Announces Expansion of Its Executive Leadership Team
Novocure Announces Expansion of Its Executive Leadership Team


Novocure (NASDAQ:NVCR) today announced an expansion of its Executive Leadership Team, effective Sept. 1, 2020, intended to further solidify executive leadership in preparation for an anticipated

Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Health Canada Authorization
Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Health Canada Authorization


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has

LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020
LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020


LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the

 Dexcom Appoints Karen Dahut to Board of Directors
 Dexcom Appoints Karen Dahut to Board of Directors


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Karen Dahut to its Board of Directors, effective immediately.



Ms

 Dexcom Appoints Karen Dahut to Board of Directors
 Dexcom Appoints Karen Dahut to Board of Directors


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Karen Dahut to its Board of Directors, effective immediately.



Ms

Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®
Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®


Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture

Evotec: Weiter auf Wachstumskurs
Evotec: Weiter auf Wachstumskurs

Am Dienstag vermeldete Evotec (WKN: 566480) einen neuen Partner-Deal mit Resolute Therapeutics und CARB-X im Bereich Infektionskrankheiten und antimikrobielle Resistenzen. Heute schiebt der

Premier, Inc. Eliminates Dual-Class Structure to Simplify Ownership; Amends and Extends Group Purchasing Agreements with Member-Owners to Support Sustainable, Long-Term Revenue Growth
Premier, Inc. Eliminates Dual-Class Structure to Simplify Ownership; Amends and Extends Group Purchasing Agreements with Member-Owners to Support Sustainable, Long-Term Revenue Growth


Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced that it has completed a corporate restructuring to eliminate its dual-class ownership structure, through an

Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company) today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent

Premier, Inc. Initiates Quarterly Cash Dividend and Declares Initial Dividend
Premier, Inc. Initiates Quarterly Cash Dividend and Declares Initial Dividend


Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.19 per share, or $0.76 on an

State of Maryland Allows Point-of-Care Testing for COVID-19; Quidel Expands Training Program
State of Maryland Allows Point-of-Care Testing for COVID-19; Quidel Expands Training Program


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that the State of Maryland

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 4, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Simulations Plus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Simulations Plus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares


Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical

NanoString Technologies Releases Operating Results for Second Quarter of 2020
NanoString Technologies Releases Operating Results for Second Quarter of 2020


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the second quarter of 2020.

Dexcom Announces Upcoming Conference Presentation
Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:




  • Quentin Blackford, Chief Operating Officer and Chief

Dexcom Announces Upcoming Conference Presentation
Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:




  • Quentin Blackford, Chief Operating Officer and Chief

Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present at the 2020 Wedbush PacGrow Healthcare Conference on August